Compare ICON & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICON | CVKD |
|---|---|---|
| Founded | 2023 | 2022 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 4.0M |
| IPO Year | 2023 | 2022 |
| Metric | ICON | CVKD |
|---|---|---|
| Price | $1.03 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 29.0K | ★ 151.5K |
| Earning Date | 08-14-2026 | 11-09-2026 |
| Dividend Yield | ★ 5092.64% | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $57.25 | N/A |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.82 |
| 52 Week High | $4.23 | $14.21 |
| Indicator | ICON | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 47.32 |
| Support Level | $0.84 | $1.00 |
| Resistance Level | $1.12 | $1.36 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 93.22 | 80.68 |
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.